{
    "info": {
        "nct_id": "NCT04429087",
        "official_title": "A First-In-human Phase I, Non-randomized, Open-label, Multi-center Dose Escalation Trial of BI 764532 Administered by Parenteral Route in Patients With Small Cell Lung Carcinoma and Other Neuroendocrine Neoplasms Expressing DLL3",
        "inclusion_criteria": "* Signed and dated, written informed consent form (ICF2, ICF3 or ICF4) in accordance with International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) - Good Clinical Practice (GCP) and local legislation prior to any trial-specific procedures, sampling, or analyses.\n* Locally advanced or metastatic cancer not amenable to curative treatment; of following histologies:\n\n  * Small cell lung carcinoma (SCLC)\n  * Large cells neuroendocrine lung carcinoma (LCNEC)\n  * Neuroendocrine carcinoma (NEC) or small cell carcinoma of any other origin\n  * Tumours must be positive for DLL3 expression (on archived tissue or instudy fresh biopsy) according to central pathology review in order to start BI 764532\n  * Patients with tumours with mixed histologies for any above type are eligible only if neuroendocrine carcinoma/small tumor cells component is predominant and represent at least 50% of the overall tumour tissue.\n* For back-fill cohorts only: patient has agreed to and signed an IC to provide mandatory pre-treatment and on-treatment fresh tumor biopsy.\n* Patient has failed or is not eligible for available standard therapies according to local guidelines. Standard therapies should include at least one line of chemotherapy that should include platinum for patients with small cells carcinoma tumors histologies.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.\n* At least one evaluable lesion outside of CNS as defined per modified Response Evaluation Criteria In Solid Tumors (RECIST) 1.1\n* Subjects with brain metastases are eligible provided they meet the following criteria:\n\n  * Radiotherapy or surgery for brain metastases was completed at least 2 weeks prior to the first administration of BI 764532\n  * Patient is off steroids for at least 7 days (physiologic doses of steroids are permitted), and the patient is off anti-epileptic drugs for at least 7 days or on stable doses of anti-epileptic drugs for malignant Central Nervous System (CNS) disease.\n* Adequate liver, bone marrow and renal organ function Further inclusion criteria apply.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "* Previous treatment with T cell Engager (TcE) or cell therapies targeting DLL3. Other DLL3 targeting agents (like Rovalpituzumab tesirine (RovaT)) are allowed only if DLL3 positivity is documented after completion of treatment with DLL3 targeting agent in post-treatment biopsy.\n* Anticoagulant treatment that cannot be safely interrupted based on opinion of the investigator if medically needed (e.g. biopsy).\n* Persistent toxicity from previous treatments that has not resolved to = Common Terminology Criteria for Adverse Events (CTCAE) Grade 1 (except for alopecia, CTCAE Grade 2 neuropathy, asthenia/fatigue or grade 2 endocrinopathies controlled by replacement therapy).\n* Patient has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of BI 764532. Physiological replacement of steroids is allowed.\n* Prior anti-cancer therapy:\n\n  * Patients who have been treated with any other anti-cancer drug within 3 weeks or within 5 half-life periods (whichever is shorter) prior to first administration of BI 764532.\n  * Patients who have been treated with extensive field radiotherapy including whole brain irradiation within 2 weeks prior to first administration of BI 764532.\n* Other active malignancy that could interfere with the prognosis and treatment of the disease of the study.\n* Major surgery within 28 days of first dose BI 764532.\n* Women who are pregnant (including those who are considered to be possibly pregnant based on the investigator's clinical judgement), nursing/breast feeding or who plan to become pregnant or nurse while in the trial or within 35 days after the last dose of study treatment.\n* Active infection that requires medical therapy or other clinically significant intervention or within 2 weeks prior to study entry confirmed (PCR test or other applicable test as per local requirements) or suspected SARS-CoV-2 infection or close contact with an individual with confirmed SARS-CoV-2 infection.\n\nFurther exclusion criteria apply.",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patient has failed or is not eligible for available standard therapies according to local guidelines. Standard therapies should include at least one line of chemotherapy that should include platinum for patients with small cells carcinoma tumors histologies.",
            "criterions": [
                {
                    "exact_snippets": "Patient has failed or is not eligible for available standard therapies according to local guidelines",
                    "criterion": "eligibility for available standard therapies",
                    "requirements": [
                        {
                            "requirement_type": "eligibility or failure",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "Standard therapies should include at least one line of chemotherapy",
                    "criterion": "prior chemotherapy lines",
                    "requirements": [
                        {
                            "requirement_type": "minimum number of lines",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "line"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "chemotherapy that should include platinum for patients with small cells carcinoma tumors histologies",
                    "criterion": "platinum chemotherapy for small cell carcinoma histology",
                    "requirements": [
                        {
                            "requirement_type": "inclusion of platinum",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "applicability",
                            "expected_value": "patients with small cell carcinoma histology"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patient is off steroids for at least 7 days (physiologic doses of steroids are permitted), and the patient is off anti-epileptic drugs for at least 7 days or on stable doses of anti-epileptic drugs for malignant Central Nervous System (CNS) disease.",
            "criterions": [
                {
                    "exact_snippets": "Patient is off steroids for at least 7 days (physiologic doses of steroids are permitted)",
                    "criterion": "steroid use",
                    "requirements": [
                        {
                            "requirement_type": "absence duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 7,
                                "unit": "days"
                            }
                        },
                        {
                            "requirement_type": "physiologic dose permitted",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "patient is off anti-epileptic drugs for at least 7 days",
                    "criterion": "anti-epileptic drug use",
                    "requirements": [
                        {
                            "requirement_type": "absence duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 7,
                                "unit": "days"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "on stable doses of anti-epileptic drugs for malignant Central Nervous System (CNS) disease",
                    "criterion": "anti-epileptic drug use for malignant CNS disease",
                    "requirements": [
                        {
                            "requirement_type": "dose stability",
                            "expected_value": "stable"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Radiotherapy or surgery for brain metastases was completed at least 2 weeks prior to the first administration of BI 764532",
            "criterions": [
                {
                    "exact_snippets": "Radiotherapy or surgery for brain metastases was completed at least 2 weeks prior to the first administration of BI 764532",
                    "criterion": "radiotherapy or surgery for brain metastases",
                    "requirements": [
                        {
                            "requirement_type": "completion_time_before_first_administration_of_BI_764532",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "weeks"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Large cells neuroendocrine lung carcinoma (LCNEC)",
            "criterions": [
                {
                    "exact_snippets": "Large cells neuroendocrine lung carcinoma (LCNEC)",
                    "criterion": "large cell neuroendocrine lung carcinoma (LCNEC)",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Neuroendocrine carcinoma (NEC) or small cell carcinoma of any other origin",
            "criterions": [
                {
                    "exact_snippets": "Neuroendocrine carcinoma (NEC)",
                    "criterion": "neuroendocrine carcinoma (NEC)",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "small cell carcinoma of any other origin",
                    "criterion": "small cell carcinoma (any origin)",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.",
            "criterions": [
                {
                    "exact_snippets": "Eastern Cooperative Oncology Group (ECOG) performance status of 0-1",
                    "criterion": "ECOG performance status",
                    "requirements": [
                        {
                            "requirement_type": "score",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": ""
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 1,
                                        "unit": ""
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* At least one evaluable lesion outside of CNS as defined per modified Response Evaluation Criteria In Solid Tumors (RECIST) 1.1",
            "criterions": [
                {
                    "exact_snippets": "At least one evaluable lesion outside of CNS as defined per modified Response Evaluation Criteria In Solid Tumors (RECIST) 1.1",
                    "criterion": "evaluable lesion outside of CNS",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "lesion"
                            }
                        },
                        {
                            "requirement_type": "location",
                            "expected_value": "outside of CNS"
                        },
                        {
                            "requirement_type": "evaluable_per_RECIST_1.1",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* For back-fill cohorts only: patient has agreed to and signed an IC to provide mandatory pre-treatment and on-treatment fresh tumor biopsy.",
            "criterions": [
                {
                    "exact_snippets": "patient has agreed to and signed an IC to provide mandatory pre-treatment and on-treatment fresh tumor biopsy",
                    "criterion": "informed consent for fresh tumor biopsy",
                    "requirements": [
                        {
                            "requirement_type": "agreement and signature",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "biopsy timing",
                            "expected_value": [
                                "pre-treatment",
                                "on-treatment"
                            ]
                        },
                        {
                            "requirement_type": "biopsy type",
                            "expected_value": "fresh tumor"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Locally advanced or metastatic cancer not amenable to curative treatment; of following histologies:",
            "criterions": [
                {
                    "exact_snippets": "Locally advanced or metastatic cancer",
                    "criterion": "cancer stage",
                    "requirements": [
                        {
                            "requirement_type": "stage",
                            "expected_value": [
                                "locally advanced",
                                "metastatic"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "not amenable to curative treatment",
                    "criterion": "amenability to curative treatment",
                    "requirements": [
                        {
                            "requirement_type": "amenability",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "of following histologies",
                    "criterion": "cancer histology",
                    "requirements": [
                        {
                            "requirement_type": "histology",
                            "expected_value": "specific histologies (to be listed elsewhere)"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Subjects with brain metastases are eligible provided they meet the following criteria:",
            "criterions": [
                {
                    "exact_snippets": "Subjects with brain metastases",
                    "criterion": "brain metastases",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients with tumours with mixed histologies for any above type are eligible only if neuroendocrine carcinoma/small tumor cells component is predominant and represent at least 50% of the overall tumour tissue.",
            "criterions": [
                {
                    "exact_snippets": "tumours with mixed histologies for any above type are eligible only if neuroendocrine carcinoma/small tumor cells component is predominant",
                    "criterion": "tumor histology",
                    "requirements": [
                        {
                            "requirement_type": "composition",
                            "expected_value": "mixed histologies"
                        },
                        {
                            "requirement_type": "predominant component",
                            "expected_value": [
                                "neuroendocrine carcinoma",
                                "small tumor cells"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "represent at least 50% of the overall tumour tissue",
                    "criterion": "neuroendocrine carcinoma/small tumor cells component proportion",
                    "requirements": [
                        {
                            "requirement_type": "proportion",
                            "expected_value": {
                                "operator": ">=",
                                "value": 50,
                                "unit": "%"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Adequate liver, bone marrow and renal organ function Further inclusion criteria apply.",
            "criterions": [
                {
                    "exact_snippets": "Adequate liver ... organ function",
                    "criterion": "liver function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Adequate ... bone marrow ... function",
                    "criterion": "bone marrow function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Adequate ... renal ... function",
                    "criterion": "renal function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Tumours must be positive for DLL3 expression (on archived tissue or instudy fresh biopsy) according to central pathology review in order to start BI 764532",
            "criterions": [
                {
                    "exact_snippets": "Tumours must be positive for DLL3 expression (on archived tissue or instudy fresh biopsy) according to central pathology review",
                    "criterion": "DLL3 expression in tumour",
                    "requirements": [
                        {
                            "requirement_type": "expression status",
                            "expected_value": "positive"
                        },
                        {
                            "requirement_type": "assessment method",
                            "expected_value": [
                                "archived tissue",
                                "instudy fresh biopsy"
                            ]
                        },
                        {
                            "requirement_type": "review authority",
                            "expected_value": "central pathology review"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Signed and dated, written informed consent form (ICF2, ICF3 or ICF4) in accordance with International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) - Good Clinical Practice (GCP) and local legislation prior to any trial-specific procedures, sampling, or analyses.",
            "criterions": [
                {
                    "exact_snippets": "Signed and dated, written informed consent form (ICF2, ICF3 or ICF4)",
                    "criterion": "informed consent form",
                    "requirements": [
                        {
                            "requirement_type": "signed",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "dated",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "written",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "form version",
                            "expected_value": [
                                "ICF2",
                                "ICF3",
                                "ICF4"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "in accordance with International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) - Good Clinical Practice (GCP) and local legislation",
                    "criterion": "informed consent process compliance",
                    "requirements": [
                        {
                            "requirement_type": "compliance standard",
                            "expected_value": [
                                "ICH-GCP",
                                "local legislation"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "prior to any trial-specific procedures, sampling, or analyses",
                    "criterion": "timing of informed consent",
                    "requirements": [
                        {
                            "requirement_type": "timing",
                            "expected_value": "before trial-specific procedures, sampling, or analyses"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Small cell lung carcinoma (SCLC)",
            "criterions": [
                {
                    "exact_snippets": "Small cell lung carcinoma (SCLC)",
                    "criterion": "small cell lung carcinoma",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "* Anticoagulant treatment that cannot be safely interrupted based on opinion of the investigator if medically needed (e.g. biopsy).",
            "criterions": [
                {
                    "exact_snippets": "Anticoagulant treatment that cannot be safely interrupted",
                    "criterion": "anticoagulant treatment",
                    "requirements": [
                        {
                            "requirement_type": "interruptibility",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "based on opinion of the investigator if medically needed (e.g. biopsy)",
                    "criterion": "investigator opinion on medical need for interruption",
                    "requirements": [
                        {
                            "requirement_type": "investigator determination of medical necessity for interruption",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Previous treatment with T cell Engager (TcE) or cell therapies targeting DLL3. Other DLL3 targeting agents (like Rovalpituzumab tesirine (RovaT)) are allowed only if DLL3 positivity is documented after completion of treatment with DLL3 targeting agent in post-treatment biopsy.",
            "criterions": [
                {
                    "exact_snippets": "Previous treatment with T cell Engager (TcE) or cell therapies targeting DLL3",
                    "criterion": "previous treatment with T cell Engager (TcE) or cell therapies targeting DLL3",
                    "requirements": [
                        {
                            "requirement_type": "history of treatment",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Other DLL3 targeting agents (like Rovalpituzumab tesirine (RovaT)) are allowed only if DLL3 positivity is documented after completion of treatment with DLL3 targeting agent in post-treatment biopsy",
                    "criterion": "DLL3 positivity in post-treatment biopsy after DLL3 targeting agent",
                    "requirements": [
                        {
                            "requirement_type": "DLL3 positivity",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "after completion of treatment with DLL3 targeting agent"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Women who are pregnant (including those who are considered to be possibly pregnant based on the investigator's clinical judgement), nursing/breast feeding or who plan to become pregnant or nurse while in the trial or within 35 days after the last dose of study treatment.",
            "criterions": [
                {
                    "exact_snippets": "Women who are pregnant (including those who are considered to be possibly pregnant based on the investigator's clinical judgement)",
                    "criterion": "pregnancy status",
                    "requirements": [
                        {
                            "requirement_type": "pregnancy",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "nursing/breast feeding",
                    "criterion": "nursing/breast feeding status",
                    "requirements": [
                        {
                            "requirement_type": "nursing/breast feeding",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "plan to become pregnant or nurse while in the trial or within 35 days after the last dose of study treatment",
                    "criterion": "future pregnancy or nursing intention",
                    "requirements": [
                        {
                            "requirement_type": "intention to become pregnant or nurse",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prior anti-cancer therapy:",
            "criterions": [
                {
                    "exact_snippets": "Prior anti-cancer therapy",
                    "criterion": "prior anti-cancer therapy",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patient has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of BI 764532. Physiological replacement of steroids is allowed.",
            "criterions": [
                {
                    "exact_snippets": "diagnosis of immunodeficiency",
                    "criterion": "immunodeficiency",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "receiving systemic steroid therapy ... within 7 days prior to the first dose of BI 764532",
                    "criterion": "systemic steroid therapy",
                    "requirements": [
                        {
                            "requirement_type": "receiving",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "time window",
                            "expected_value": {
                                "operator": "<=",
                                "value": 7,
                                "unit": "days prior to first dose"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "any other form of immunosuppressive therapy within 7 days prior to the first dose of BI 764532",
                    "criterion": "immunosuppressive therapy (other than systemic steroids)",
                    "requirements": [
                        {
                            "requirement_type": "receiving",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "time window",
                            "expected_value": {
                                "operator": "<=",
                                "value": 7,
                                "unit": "days prior to first dose"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Major surgery within 28 days of first dose BI 764532.",
            "criterions": [
                {
                    "exact_snippets": "Major surgery within 28 days of first dose BI 764532.",
                    "criterion": "major surgery",
                    "requirements": [
                        {
                            "requirement_type": "time since event",
                            "expected_value": {
                                "operator": "<=",
                                "value": 28,
                                "unit": "days"
                            }
                        },
                        {
                            "requirement_type": "relative to",
                            "expected_value": "first dose BI 764532"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Persistent toxicity from previous treatments that has not resolved to = Common Terminology Criteria for Adverse Events (CTCAE) Grade 1 (except for alopecia, CTCAE Grade 2 neuropathy, asthenia/fatigue or grade 2 endocrinopathies controlled by replacement therapy).",
            "criterions": [
                {
                    "exact_snippets": "Persistent toxicity from previous treatments that has not resolved to = Common Terminology Criteria for Adverse Events (CTCAE) Grade 1 (except for alopecia, CTCAE Grade 2 neuropathy, asthenia/fatigue or grade 2 endocrinopathies controlled by replacement therapy)",
                    "criterion": "persistent toxicity from previous treatments",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "CTCAE Grade"
                            }
                        },
                        {
                            "requirement_type": "exceptions",
                            "expected_value": [
                                "alopecia",
                                "CTCAE Grade 2 neuropathy",
                                "asthenia/fatigue",
                                "grade 2 endocrinopathies controlled by replacement therapy"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Other active malignancy that could interfere with the prognosis and treatment of the disease of the study.",
            "criterions": [
                {
                    "exact_snippets": "Other active malignancy that could interfere with the prognosis and treatment of the disease of the study.",
                    "criterion": "other active malignancy",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "potential to interfere with prognosis and treatment of the disease of the study",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients who have been treated with extensive field radiotherapy including whole brain irradiation within 2 weeks prior to first administration of BI 764532.",
            "criterions": [
                {
                    "exact_snippets": "treated with extensive field radiotherapy including whole brain irradiation within 2 weeks prior to first administration of BI 764532",
                    "criterion": "extensive field radiotherapy (including whole brain irradiation)",
                    "requirements": [
                        {
                            "requirement_type": "treatment timing",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "weeks prior to first administration of BI 764532"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients who have been treated with any other anti-cancer drug within 3 weeks or within 5 half-life periods (whichever is shorter) prior to first administration of BI 764532.",
            "criterions": [
                {
                    "exact_snippets": "treated with any other anti-cancer drug within 3 weeks or within 5 half-life periods (whichever is shorter) prior to first administration of BI 764532",
                    "criterion": "prior anti-cancer drug treatment",
                    "requirements": [
                        {
                            "requirement_type": "recency of treatment",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 3,
                                        "unit": "weeks"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 5,
                                        "unit": "half-life periods"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [],
    "failed_exclusion": [
        {
            "line": "Further exclusion criteria apply.",
            "criterions": []
        },
        {
            "line": "* Active infection that requires medical therapy or other clinically significant intervention or within 2 weeks prior to study entry confirmed (PCR test or other applicable test as per local requirements) or suspected SARS-CoV-2 infection or close contact with an individual with confirmed SARS-CoV-2 infection.",
            "criterions": [
                {
                    "exact_snippets": "Active infection that requires medical therapy or other clinically significant intervention",
                    "criterion": "active infection",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": "requires medical therapy or other clinically significant intervention"
                        }
                    ]
                },
                {
                    "exact_snippets": "active infection ... within 2 weeks prior to study entry",
                    "criterion": "active infection",
                    "requirements": [
                        {
                            "requirement_type": "time since infection",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "weeks"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "confirmed (PCR test or other applicable test as per local requirements) ... SARS-CoV-2 infection",
                    "criterion": "SARS-CoV-2 infection",
                    "requirements": [
                        {
                            "requirement_type": "confirmation",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "suspected SARS-CoV-2 infection",
                    "criterion": "SARS-CoV-2 infection",
                    "requirements": [
                        {
                            "requirement_type": "suspected",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "close contact with an individual with confirmed SARS-CoV-2 infection",
                    "criterion": "close contact with individual with confirmed SARS-CoV-2 infection",
                    "requirements": [
                        {
                            "requirement_type": "exposure",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "failed_miscellaneous": []
}